Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Receptor down regulation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Receptor down regulation. Displaying page 1 of 1.
    EudraCT Number: 2010-023987-41 Sponsor Protocol Number: 2010.2611 Start Date*: 2011-06-24
    Sponsor Name:University Medical Center Groningen
    Full Title: In vivo imaging of the effect of fulvestrant on availability of estrogen receptor binding sites in metastatic breast tumor lesions using [18F]FES-PET
    Medical condition: Estrogen Receptor-positive metastatic breast cancer patients that will be treated with fulvestrant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005160-27 Sponsor Protocol Number: NAI009 Start Date*: 2009-02-04
    Sponsor Name:The University of Dundee
    Full Title: A proof of concept study to evaluate rebound trough airway hyper-responsiveness after single and chronic dosing with levosalbutamol and racemic salbutamol in persistent asthmatics
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003617-16 Sponsor Protocol Number: D6997C00003 (9238IL/0065) Start Date*: 2004-12-24
    Sponsor Name:AstraZeneca Österreich GmbH
    Full Title: A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg ...
    Medical condition: Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015476-98 Sponsor Protocol Number: 1200.75 Start Date*: 2010-05-17
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one pri...
    Medical condition: patients with metastatic HER2 over-expressing breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) FR (Completed) AT (Completed) IT (Completed) ES (Completed) FI (Prematurely Ended) LT (Completed) LV (Completed) SI (Completed) GB (Completed) IE (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-000971-34 Sponsor Protocol Number: 01052013 Start Date*: 2013-08-01
    Sponsor Name:Jørgen Agnholt
    Full Title: Mucosal immune regulation by high dose vitamin D treatment in Crohn’s disease
    Medical condition: Active Crohn's Disease in colon and/or terminal ileum
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10011408 Crohns disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 22:16:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA